Company Overview

In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications.
 
Fab’entech is a privately owned pharmaceutical company headquartered in Lyon (France) and created in 2009. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease.

Immunotherapies to address situations of emergency

​After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is now focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

Board

  • Philippe ARCHINARD: Chairman of the Supervisory Board, Institut Mérieux
  • Bertrand LEPINE: Founder & Family shareholder representative
  • Frédéric HAMMEL: Elaia
  • Marielle MAILHES: BPI Investissement, Definvest
  • Sandra DUBOS: Kreaxi
  • Guillaume HEMMERLE: Sigma Gestion
  • Albert SAPORTA: Censor

MANAGEMENT TEAM

  • Sébastien IVA: Chief Executive Officer, Chairman of the Management Board
  • Antoine GAILLARD: Head of Pharmaceutical Affairs
  • Cécile HERBRETEAU DELALE: Head of Research & Development
  • Ludovic NGUYEN: Head of Industrial Operations

PARTNERS AND SUPPORTS